Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges
Open Access
- 5 June 2021
- Vol. 13 (6), 1082
- https://doi.org/10.3390/v13061082
Abstract
Oncolytic viruses have emerged as a promising strategy for cancer therapy due to their dual ability to selectively infect and lyse tumor cells and to induce systemic anti-tumor immunity. Among various candidate viruses, coxsackievirus group B (CVBs) have attracted increasing attention in recent years. CVBs are a group of small, non-enveloped, single-stranded, positive-sense RNA viruses, belonging to species human Enterovirus B in the genus Enterovirus of the family Picornaviridae. Preclinical studies have demonstrated potent anti-tumor activities for CVBs, particularly type 3, against multiple cancer types, including lung, breast, and colorectal cancer. Various approaches have been proposed or applied to enhance the safety and specificity of CVBs towards tumor cells and to further increase their anti-tumor efficacy. This review summarizes current knowledge and strategies for developing CVBs as oncolytic viruses for cancer virotherapy. The challenges arising from these studies and future prospects are also discussed in this review.Keywords
Funding Information
- Canadian Cancer Society (N/A)
- British Columbia Lung Association (N/A)
- Providence Health Care Research Institute (PHCRI) and Vancouver Coastal Health Research Institute (N/A)
This publication has 129 references indexed in Scilit:
- Targeting PD-1/PD-L1 interactions for cancer immunotherapyOncoImmunology, 2012
- Molecular determinants of disease in coxsackievirus B1 murine infectionJournal of Medical Virology, 2011
- Chromosomal Integration of Adenoviral Vector DNA In VivoJournal of Virology, 2010
- Impaired interferon signaling is a common immune defect in human cancerProceedings of the National Academy of Sciences of the United States of America, 2009
- Immunoregulatory mechanisms triggered by viral infections protect from type 1 diabetes in miceJCI Insight, 2009
- Anticancer oncolytic activity of respiratory syncytial virusCancer Gene Therapy, 2009
- Picornavirus Genome ReplicationOnline Journal of Public Health Informatics, 2008
- The Crystal Structure of Coxsackievirus B3 RNA-Dependent RNA Polymerase in Complex with Its Protein Primer VPg Confirms the Existence of a Second VPg Binding Site on Picornaviridae PolymerasesJournal of Virology, 2008
- MicroRNA Signatures in Human CancersNature Reviews Cancer, 2006
- MicroRNA expression profiles classify human cancersNature, 2005